Table 4.
Recommended Dosing for Patients Prescribed Doses of 0.24 mg/kg/Week Based Upon Available Cartridge size39
Weight (kg) | Dose (mg) |
---|---|
11.5–13.9 | 3 |
14–16.4 | 3.6 |
16.5–19.9 | 4.3 |
20–23.9 | 5.2 |
24–28.9 | 6.3 |
29–34.9 | 7.6 |
35–41.9 | 9.1 |
42–50.9 | 11 |
51–60.4 | 13.3 |
60.5–69.9 | 15.2 (using 2 cartridges of 7.6 mg) |
70–84.9 | 18.2 (using 2 cartridges of 9.1 mg) |
85–100 | 22 (using 2 cartridges of 11 mg) |
Note: Reproduced with permission from Ascendis. SKYTROFA™ (lonapegsomatropin-tcgd) for injection, for subcutaneous use; 2021. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761177lbl.pdf. © 2022 Ascendis Pharma. All rights reserved. SKYTROFA™, Ascendis®, TransCon®, the Ascendis Pharma logo and the company logo are trademarks owned by the Ascendis Pharma Group.39